ChartMill assigns a Buy % Consensus number of 72% to TPTX. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-06-13 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2022-06-06 | Cowen & Co. | Downgrade | Outperform -> Market Perform |
| 2022-06-06 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2022-06-03 | Wedbush | Downgrade | Outperform -> Neutral |
| 2022-05-24 | Goldman Sachs | Maintains | Buy |
| 2022-05-20 | B of A Securities | Initiate | Buy |
| 2022-05-11 | SVB Leerink | Maintains | Outperform |
| 2022-03-01 | Stifel | Maintains | Hold |
| 2022-02-10 | Wells Fargo | Maintains | Overweight |
| 2022-01-21 | Oppenheimer | Maintains | Outperform |
| 2021-12-07 | Cowen & Co. | Initiate | Outperform |
| 2021-11-10 | Oppenheimer | Maintains | Outperform |
| 2021-10-12 | HC Wainwright & Co. | Maintains | Buy |
| 2021-10-11 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2021-09-30 | Stifel | Initiate | Hold |
| 2021-04-06 | HC Wainwright & Co. | Maintains | Buy |
15 analysts have analysed TPTX and the average price target is 74.9 USD. This implies a price decrease of -1.46% is expected in the next year compared to the current price of 76.01.
The consensus rating for TURNING POINT THERAPEUTICS I (TPTX) is 72 / 100 . This indicates that analysts generally have a positive outlook on the stock.